Pancreatic Cancer Research

ResearcherUniversity of UtahActive in the last 2 years

Chris Nevala-Plagemann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4048-2692; OpenAlex author ID A5080264243. Sources: OpenAlex.

Their work

Papers
12 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 12

  1. Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial. Co-author DOI 10.1038/s41591-026-04705-y↗
  2. KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamanetworkopen.2024.53588↗
  3. Gemcitabine-induced myositis in a patient with pancreatic cancer. First author DOI 10.1136/bcr-2024-259660↗
  4. NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? Co-author DOI 10.1038/s41571-024-00896-w↗
  5. Reply to 'NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3'. Co-author DOI 10.1038/s41571-024-00953-4↗
  6. Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations … Co-author DOI 10.1158/1078-0432.ccr-22-3724↗
  7. Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. First author DOI 10.1186/s12885-022-10130-4↗
  8. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001844↗
  9. Emerging Treatment Strategies in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001845↗
  10. Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. First author DOI 10.1177/17588359211045861↗
  11. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Co-author DOI 10.1038/s41571-019-0281-6↗
  12. Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. First author DOI 10.1200/po.20.00052↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ignacio Garrido‐Laguna · 11 shared papers, 2020–2025 · strength 2.66
  2. Vaia Florou · 5 shared papers, 2020–2025 · strength 1.11
  3. Zach Rubnitz · 2 shared papers, 2025 · strength 0.63
  4. Heloisa Prado Soares · 2 shared papers, 2023–2025 · strength 0.43
  5. Manuel M. Hidalgo · 2 shared papers, 2020–2026 · strength 0.40
  6. Teresa Mercade Macarulla · 2 shared papers, 2021–2026 · strength 0.37
  7. Thierry Conroy · 1 shared paper, 2024 · strength 0.36
  8. Laura K. Miotke · 2 shared papers, 2021–2022 · strength 0.34
  9. Carter Norton · 1 shared paper, 2025 · strength 0.27
  10. Siddharth Kumar Iyengar · 1 shared paper, 2021 · strength 0.22
  11. Mireya Cazorla · 1 shared paper, 2026 · strength 0.21
  12. Andrés Muñoz · 1 shared paper, 2026 · strength 0.21
  13. Vivek Sharma · 1 shared paper, 2026 · strength 0.21
  14. Luis Alfonso Rojas · 1 shared paper, 2026 · strength 0.21
  15. Rocio García‐Carbonero · 1 shared paper, 2026 · strength 0.21
  16. Edward Jae-Hoon Kim · 1 shared paper, 2026 · strength 0.21
  17. Roberto Pazo-Cid · 1 shared paper, 2026 · strength 0.21
  18. Carmen Guillén‐Ponce · 1 shared paper, 2026 · strength 0.21
  19. Eva Martínez de Castro · 1 shared paper, 2026 · strength 0.21
  20. Helena Verdaguer · 1 shared paper, 2021 · strength 0.16
  21. Margaret Kelsey Baron · 1 shared paper, 2021 · strength 0.16
  22. Andrew D. Trunk · 1 shared paper, 2021 · strength 0.16
  23. Rachna T. Shroff · 1 shared paper, 2023 · strength 0.16
  24. Kajsa E. Affolter · 1 shared paper, 2023 · strength 0.16
  25. Courtney L. Scaife · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.